July 23, 2021

Placebo response is a major source of noise in trial data analysis, muddying the results and making it more difficult to detect true treatment effect. We know that it’s a pressing problem for clinical trials that needs solving, but where does it come from in the first place? Patient psychology, expectations and baseline severity of the disease play a significant part of a patient’s placebo responsiveness.

July 9, 2021

When we think about patient characteristics that influence health, disease, and clinical research, we tend to think about things like vital statistics, medical history and genetic makeup – while patient personality or psychology is often overlooked. In reality, the importance of personality has been under scrutiny for centuries and dates back to Greek and Roman times

June 17, 2021

As in many other diseases (e.g. pain, osteoarthritis, rheumatoid arthritis, Parkinson’s Disease, etc ), patients participating in clinical trials for IBD treatments may experience a pronounced placebo effect or placebo response. As IBD is a chronic disease, efficacy is comprised of improvement rates as well as remission rates; unfortunately, both are influenced by placebo response, albeit at different rates.

May 26, 2021

Adjustment for covariates helps clinical trial statisticians demonstrate differences in drug effect between groups of people. In this blog, we discuss what this means and how it can help improve analysis and interpretation of clinical trial data.

May 6, 2021

The current abstract is the result of a collaboration between Unity biotechnology and Tools4 patient As you know, the placebo response is one of the major sources of variability in randomized clinical trials As a result, many trials fail due to a high placebo response. Unfortunately, this is also true in OA studies. However, within Tools4Patient, we have developed a Machine-Learning model named Placebell©™ that can overcome this placebo challenge. This machine -learning

May 6, 2021

LEARNING EFFECT & EVALUATION ERROR At Tools4Patient, we are working on the prediction of placebo response and especially the placebo response with endpoints assessing the patients’ pain. As you know, these endpoints represent most of the efficacy endpoints in Osteoarthritis Randomized Clinical Trials. Nevertheless, the assessment of pain is, by nature, subjective and the risk is high